Tandem Diabetes Care Inc (TNDM)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Tandem Diabetes Care Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 20.10 $ — 55% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
3/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 31.9%
- Exp. sales growth 3Y > 5% 9.0%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 9.0%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 1
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% -142.7%
- ROCE > 15% -12.2%
- Expected return > 10% 6.6%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 8.2% failed
- More than 10% revenue growth is expected for the coming year 12.3% passed
- Share count grows by less than 3% a year 1.6% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 5.0% failed
- Gross margin at 40% or higher and without meaningful erosion 52.3% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 506 m failed
- Return on capital at 15% or higher, or up versus two years ago -12.2% failed
- Insiders hold at least 10% or are net buyers 1.0% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 41.9% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 21
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.68 | -0.99 – -0.41 | 1,076 | 73.5% | 19 |
| 12/31/2027 | 0.11 | -0.35 – 0.58 | 1,206 | 115.6% | 19 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.34 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.01 | – | 283 | 43.60 | 0.30 | 11 | 8 |
| 2025: Q1 | -1.97 | – | 234 | 22.30 | -55.70 | -18 | -21 |
| 2025: Q2 | -0.78 | – | 241 | 8.50 | -21.80 | -10 | -16 |
| 2025: Q3 | -0.31 | – | 249 | -31.40 | -8.50 | 8 | 4 |
| 2025: Q4 | -0.01 | -175.90 | 290 | 2.70 | -0.20 | 10 | 3 |
| 2026: Q1 | -0.30 | – | 247 | 5.50 | -8.20 | 11 | 5 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 84 | -78 | -83 | -27.30 | -61 | -6 | 112 |
| 2017 | 108 | -63 | -73 | -12.86 | -66 | -29 | 95 |
| 2018 | 184 | -45 | -123 | -2.55 | -8 | 131 | 206 |
| 2019 | 362 | -17 | -25 | -0.42 | 42 | 195 | 326 |
| 2020 | 499 | -8 | -34 | -0.56 | 25 | 366 | 716 |
| 2021 | 703 | 23 | 16 | 0.24 | 111 | 433 | 905 |
| 2022 | 801 | -93 | -95 | -1.47 | 50 | 440 | 1,053 |
| 2023 | 748 | -233 | -223 | -3.43 | -32 | 314 | 953 |
| 2024 | 940 | -99 | -96 | -1.47 | 24 | 263 | 968 |
| 2025 | 1,015 | -78 | -205 | -3.04 | -10 | 155 | 881 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Tandem Diabetes Care, Inc. entwirft, entwickelt und vermarktet Technologielösungen für Menschen mit Diabetes in den USA und international.
| CEO Insider Trades (12 Mo.) | buying own stock |
|---|---|
| Employees | 2,500 |
| Headquarters | San Diego, CA |
| Address | 12400 High Bluff Drive, 92130 San Diego, United States |
| Phone | 858 366 6900 |
| Website | tandemdiabetes.com |
| IPO Date | 14. Nov 2013 |
| ISIN | US8753722037 |
| Stock Split | 1:10 on 10/10/2017 |
Management
| Name | Title | Birth Year |
|---|---|---|
| John F. Sheridan | President, CEO & Director | 1955 |
| Leigh A. Vosseller | Executive VP, CFO & Treasurer | 1973 |
| Shannon M. Hansen J.D. | Executive VP, Chief Legal, Privacy & Compliance Officer and Secretary | 1966 |
| Elizabeth Anne Gasser | Executive VP and Chief Strategy & Product Officer | 1976 |
| Jean-Claude E. Kyrillos | Executive VP & COO | 1964 |
| Rick A. Carpenter | Executive VP & CTO | 1963 |
| Susan M. Morrison | Executive VP & Chief Administrative Officer | 1979 |
| Tom Fox | Executive VP & Chief Human Resources Officer | – |
| Jordan Pinsker M.D. | Chief Medical Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 15. Jul 2026 | Kyrillos Jean-Claude | EVP & Chief Operating Officer | Other | 1,926 | 15.28 | 29,429 |
| 15. Jul 2026 | Kyrillos Jean-Claude | EVP & Chief Operating Officer | Other | 3,636 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.